Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | KYNU | Q16719 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461987 | 1.00 | MAPT (0.50) | MAPTGAAALDH1A1HSD17B10CFTR | |
| SCHEMBL13928585 | 0.85 | MAPT (0.47) | MAPTGAAALDH1A1HSD17B10CFTR | |
| SCHEMBL4161540 | 0.85 | MAPT (0.47) | MAPTGAAALDH1A1HSD17B10CFTR | |
| SCHEMBL2267543 | 0.84 | MAPT (0.46) | MAPTGAAALDH1A1HSD17B10CFTR | |
| SCHEMBL9068076 | 0.80 | SLC1A1 (0.46) | MAPTGAAALDH1A1HSD17B10CFTR | |
| SCHEMBL7129156 | 0.77 | SRC (0.59) | MAPTGAAALDH1A1HSD17B10CFTR | |
| Anthranilic Acid SCHEMBL2255713 | 0.77 | SLC7A5 (0.52) | MAPTGAAALDH1A1HSD17B10CFTR | |
| SCHEMBL2941784 | 0.76 | ALDH1A1 (0.52) | MAPTGAAALDH1A1HSD17B10CFTR | |
| Anthranilamide SCHEMBL2834554 | 0.75 | SLC7A5 (0.50) | MAPTGAAALDH1A1HSD17B10CFTR | |
| SCHEMBL15361966 | 0.74 | MAPT (0.47) | MAPTGAAALDH1A1HSD17B10CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3513800-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | Cornell University (US) | 2019-07-24 | — | — | EP | claimed |
| US-20150010588-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | CORNELL UNIVERSITY (US) | 2015-01-08 | — | — | US | claimed |
| US-20140378396-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | STEALTH BIOTHERAPEUTICS CORP (MC) | 2014-12-25 | — | — | US | claimed |
| EP-2768516-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | Cornell University (US) | 2014-08-27 | — | — | EP | claimed |
| WO-2013059071-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | CORNELL UNIVERSITY (US) | 2013-04-25 | — | — | WO | claimed |
| EP-4397314-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240156892-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11931397-B2 | Methods and compositions for the treatment of Sengers syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2004070054-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-1141375-A4 | METALLOPEPTIDE COMBINATORIAL LIBRARIES AND APPLICATIONS | PALATIN TECHNOLOGIES INC (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-1208377-A1 | MELANOCORTIN METALLOPEPTIDE CONSTRUCTS, COMBINATORIAL LIBRARIES AND APPLICATIONS | Palatin Technologies, Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| US-20020012948-A1 | Metallopeptide combinatorial libraries and applications | PALATIN TECHNOLOGIES, INC. | 2002-01-31 | — | — | US | disclosed |
| US-6331285-B1 | PEPTIDE, PEPTIDOMIMETIC, PEPTIDE-LIKE AND METALLO-CONSTRUCTS, FOR USE IN RECEPTOR-SPECIFIC COMPOSITIONS FOR BIOLOGICAL, PHARMACEUTICAL AND RADIOPHARMACEUTICAL APPLICATIONS, CONFORMATIONALLY FIXED, | PALATIN TECHNOLOGIES, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1141375-A1 | METALLOPEPTIDE COMBINATORIAL LIBRARIES AND APPLICATIONS | Palatin Technologies, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001013112-A1 | MELANOCORTIN METALLOPEPTIDE CONSTRUCTS, COMBINATORIAL LIBRARIES AND APPLICATIONS | PALATIN TECHNOLOGIES, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000036136-A1 | METALLOPEPTIDE COMBINATORIAL LIBRARIES AND APPLICATIONS | PALATIN TECHNOLOGIES, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378396-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | PDF, AIFM1, PITRM1 | MAPT 4668/4885GAA 1866/4885ALDH1A1 4313/4885 |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | MAPT 1279/4885GAA 310/4885ALDH1A1 2572/4885 |
| US-20020012948-A1 | Metallopeptide combinatorial libraries and applications | SPPL2B, METAP2, PTMS | MAPT 2824/4885GAA 1832/4885ALDH1A1 4694/4885 |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | OAT, TFAM, OTC | MAPT 1274/4885GAA 136/4885ALDH1A1 2100/4885 |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | OPRL1, TSG101, NGF | MAPT 1390/4885GAA 2058/4885ALDH1A1 3899/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | MAPT 35/4885GAA 2104/4885ALDH1A1 4705/4885 |
| US-20150010588-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | PDF, ARG2, NLN | MAPT 4500/4885GAA 1141/4885ALDH1A1 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.